Genital Herpes-API Insights, 2017
[Report Updated: 30-05-2017]

Published by Delve Insight: 30 May 2017 | 84150
Related Topics: FDA

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Genital
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email pdb@bioportfolio.co.uk.

Introduction

The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.

India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.

DelveInsight’s, Genital Herpes -API Insights, 2017 Report describes the current therapeutics that are propelling the pharmaceutical markets worldwide. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the Genital Herpes. It also provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent and patent exclusivity information. The research analysis also presents the global sales data till 2016.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global Market therapeutics scenario for Genital Herpes.

• A review of the marketed products under prescription for Genital Herpes, regulatory information and marketing status.

• Coverage of global patent coverage and detailed commentaries on the US patent challenges.

• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

• Product profiles for marketed products for Genital Herpes with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

• Coverage of API Manufacturers for Genital Herpes drugs in the United States, Europe and Asian Regions with location details.

• Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Genital Herpes drugs.

• Key discontinued Marketed products.

• Global Sales Figure from 2012-2016.Reasons to Buy

• Evaluate the marketing status and exclusivity details of Genital Herpes key products to exploit opportunities for generic drug development opportunities.

• Key players in the pharmaceutical industry.

•Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Genital Herpes.

• API intelligence over marketed drugs for Genital Herpes and gaining primary intelligence over active ingredients manufacturers across the globe.

• Uncovering opportunities in the rapidly growing the US markets.

Table of Contents
for Genital Herpes-API Insights, 2017 [Report Updated: 30-05-2017]

List Of Tables
in Genital Herpes-API Insights, 2017 [Report Updated: 30-05-2017]

Genital Herpes Therapeutic Market, US, Marketed Drugs by Application Type, 2017

Genital Herpes Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017

Genital Herpes Therapeutic Market, US, (Year), 2017

Genital Herpes Marketed Drugs, API Manufacturers by US DMF Status, 2017

Genital Herpes Marketed Drugs, US DMF Status Drug Specific (Number), 2017

Genital Herpes Therapeutic Market, Global Sales (in million USD), 2017

Genital Herpes Marketed Drugs, API Manufacturers, Global, 2017

Discontinued Drugs for Genital Herpes, 2017

List Of Figures, Charts and Diagrams
in Genital Herpes-API Insights, 2017 [Report Updated: 30-05-2017]

Genital Herpes Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017

Genital Herpes Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017

Genital Herpes Therapeutic Market, US, (Year), 2017

Genital Herpes Marketed Drugs, API Manufacturers by US DMF Status (%), 2017

Genital Herpes Marketed Drugs, US DMF Status Drug Specific (Number), 2017

Genital Herpes Therapeutic Market, Global Sales (in million USD), 2017

Genital Herpes Marketed Drugs, Patent/Exclusivity Expiry (Year), 2017

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

84150 | DII2017API072

Number of Pages

60

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Genital Herpes - Epidemiology Forecast To 2023
DelveInsight “Genital Herpes - Epidemiology Forecast To 2023” provides an overview of the epidemiolo...
31 May 2017 by Delve Insight USD $2,338 (normally
USD $2,751)
More Info
SAVE 15% today! Genital Herpes - Market Insights, Epidemiology and Market Forecast-2023
Note*: This report requires 5-7 business days to complete.DelveInsight’s Genital Herpes - Market Ins...
30 May 2017 by Delve Insight USD $4,208 (normally
USD $4,951)
More Info
SAVE 15% today! Genital Herpes-Pipeline Insights, 2017
DelveInsight’s, “ Genital Herpes-Pipeline Insights, 2017”, report provides in depth insights on the ...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata)-Pipeline Insights, 2017
DelveInsight’s, “ Genital Warts (Condylomata Acuminata)-Pipeline Insights, 2017”, report provides in...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Genital Herpes-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Genital Herpes-Global API Manufacturers, Marketed and Phase III Drugs Landsc...
30 May 2017 by Delve Insight USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Genital Warts (Condylomata Acuminata)-Global API Manufacturers, Marketed and...
30 May 2017 by Delve Insight USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Genital Herpes - Pipeline Review, H1 2017
Genital Herpes - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and He...
22 Mar 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2016
Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2016SummaryGlobalData's cli...
29 Feb 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Genital Herpes Global Clinical Trials Review, H1, 2016
Genital Herpes Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Ge...
29 Feb 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Genital Herpes Treatment Market: By Product type (Acyclovir, Famciclovir, Valacyclovir), By Distribution Channel (Hospital Pharmacies, General Pharmacies, Drug stores) & Geography -Forecast (2016-2021)
General herpes is categorised as a sexually transmitted disease/infection (STI) which is caused by h...
18 Feb 2016 by USD $4,463 (normally
USD $5,251)
More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

We Stock...